These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38850781)

  • 1. Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment.
    Dubey R; Makhija R; Sharma A; Sahu A; Asati V
    Bioorg Chem; 2024 Aug; 149():107508. PubMed ID: 38850781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
    Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
    Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
    Nandi S; Dey R; Dey S; Samadder A; Saxena AK
    Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
    Shi X; Quan Y; Wang Y; Wang Y; Li Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Perspectives in the Development of Novel EGFR Inhibitors for the Treatment of NSCLC.
    Makhija R; Sharma A; Dubey R; Asati V
    Mini Rev Med Chem; 2024; 24(19):1746-1783. PubMed ID: 38584547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
    Sánchez-Martínez C; Lallena MJ; Sanfeliciano SG; de Dios A
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126637. PubMed ID: 31477350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
    Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
    Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
    Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors.
    Zhang H; Lin G; Jia S; Wu J; Zhang Y; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
    Bioorg Chem; 2024 Jul; 148():107456. PubMed ID: 38761706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
    Xu Z; Liu Y; Song B; Ren B; Xu X; Lin R; Zhu X; Chen C; Yang S; Zhu Y; Jiang W; Li W; Xia Y; Hu L; Chen S; Chan CC; Li J; Zhang X; Yang L; Tian X; Ding CZ
    Bioorg Med Chem Lett; 2024 Jul; 107():129769. PubMed ID: 38670537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, Docking Studies into CDK-2 and Anticancer Activity of New Derivatives Based Pyrimidine Scaffold and Their Derived Glycosides.
    Rahman AAHA; Nassar IF; Shaban AKF; El-Kady DS; Awad HM; El Sayed WA
    Mini Rev Med Chem; 2019; 19(13):1093-1110. PubMed ID: 30864522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
    Jorda R; Havlíček L; Šturc A; Tušková D; Daumová L; Alam M; Škerlová J; Nekardová M; Peřina M; Pospíšil T; Široká J; Urbánek L; Pachl P; Řezáčová P; Strnad M; Klener P; Kryštof V
    J Med Chem; 2019 May; 62(9):4606-4623. PubMed ID: 30943029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
    Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
    Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy.
    Wang YT; Jiang SQ; Zhang SL
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38998978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure-activity relationship.
    Pal R; Matada GSP; Teli G; Saha M; Patel R
    Bioorg Chem; 2024 Nov; 152():107696. PubMed ID: 39167870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.